Streetbeat News

Earnings

CHRS

Coherus BioSciences (NASDAQ:CHRS) reported Q4 earnings with an EPS of $-0.62, missing estimates by -417.0% against an expected $-0.12. Revenue increased by $46.17 million from the same period last year. Despite beating EPS estimates in Q3 2023, the share price dropped by 30.0% the following day. The company's past earnings performance shows a pattern of fluctuating EPS and revenue figures.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 8:05 pm

FTCI

FTC Solar (NASDAQ:FTCI) reported Q4 2023 adjusted EPS of $(0.08), missing the $(0.07) estimate, but sales of $23.201M beat the $23.116M estimate, marking an 11.51% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 8:03 pm

CHRS

Coherus BioSciences (NASDAQ:CHRS) reported Q4 2023 adjusted EPS of $(0.62), missing the $(0.12) estimate, with sales of $91.524M also missing the $96.400M estimate. This represents a 101.81% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 8:03 pm

IVA

Inventiva (NASDAQ:IVA), a biopharmaceutical company, will present the results of the LEGEND Phase IIa trial on March 19, 2024. The trial evaluates lanifibranor in combination with empagliflozin for treating MASH/NASH and T2D. The study aims to assess the safety and efficacy of this combination, with primary efficacy endpoint being the change in Hemoglobin A1c at week 24. Lanifibranor, a pan-PPAR agonist, has received FDA Breakthrough Therapy and Fast Track designation for MASH/NASH treatment.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 8:01 pm

ATEC

Alphatec Holdings (NASDAQ:ATEC) has received mixed analyst ratings over the past three months, with a positive shift in the 12-month price target to an average of $19.00, up 18.75% from $16.00. The company, specializing in spinal surgery technology, shows a strong revenue growth rate of 30.23% as of December 31, 2023, but struggles with profitability and high debt levels. Analysts from Needham and HC Wainwright & Co. maintain 'Buy' ratings with updated price targets.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 8:00 pm

DIS

Trian Fund Management, L.P. has nominated Nelson Peltz and Jay Rasulo for election to Disney's Board of Directors, opposing the reelection of incumbents Michael B.G. Froman and Maria Elena Lagomasino. Trian criticizes Disney's current board for deflecting from performance issues and misrepresenting Trian's contributions, highlighting Disney's underperformance in stock and earnings. Trian, owning over $3.5 billion in Disney shares, advocates for change to improve governance and oversight, emphasizing Disney's potential for future outperformance.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 7:40 pm

AADI

Aadi Bioscience shares surged following the announcement of their Q4 financial results, which exceeded market expectations.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 7:33 pm

AWRE

Aware Inc. shares have declined following the announcement of a year-over-year decrease in its Q4 earnings per share (EPS) results.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 7:30 pm

DOMA

Doma Holdings reported its Q4 financial results, leading to a decrease in its share price.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 7:28 pm

ADBE

Adobe Inc (NASDAQ:ADBE) is set to report its Q1 financial results, with analysts expecting strong growth trends and a focus on generative AI-enabled products. Revenue is anticipated at $5.14 billion, with earnings per share at $4.38. Analysts are optimistic, citing Adobe's AI innovations and potential for increased monetization. However, there are mixed feelings about AI's impact on Adobe's existing products. The company's decision to abandon its merger with Figma and its upcoming Adobe Summit event are also key points of interest.

Portfolio Pulse from Chris Katje

March 13, 2024 | 7:18 pm